Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the combination of bortezomib (Velcade),
dexamethasone (Decadron) and rituximab (Rituxan) is effective in treating Waldenstrom's
macroglobulinemia.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Millennium Pharmaceuticals, Inc.